What is Interpace Biosciences?
Interpace Biosciences is an emerging leader in personalized medicine, providing specialized services across the therapeutic value chain. Their offerings span early diagnosis, prognostic planning, and targeted therapeutic applications. Through Interpace Diagnostics, the company delivers clinically useful molecular diagnostic tests, bioinformatics, and pathology services. These services are designed to evaluate cancer risk by leveraging cutting-edge technology for improved patient diagnosis and management. Interpace currently offers five commercialized molecular tests, including PancraGEN® for pancreatic cancer diagnosis and prognosis, PanDNA® for a molecular snapshot, ThyGeNEXT® for thyroid cancer diagnosis, ThyraMIR®v2 for thyroid cancer diagnosis in conjunction with ThyGeNEXT®, and RespriDX® for differentiating lung cancer origin. Additionally, BarreGEN®, an assay for assessing the risk of Barrett's Esophagus progression to esophageal cancer, is in a clinical evaluation program (CEP) to gather data for safety, performance, and potential payer reimbursement.
How much funding has Interpace Biosciences raised?
Interpace Biosciences has raised a total of $3.6M across 1 funding round:
Stock Offering
$3.6M
Stock Issuance/Offering (2017): $3.6M, investors not publicly disclosed
What's next for Interpace Biosciences?
The substantial enterprise-level funding and recent strategic investment position Interpace Biosciences for accelerated growth and market expansion. This capital infusion is expected to fuel further development of their diagnostic platforms and enhance their service offerings in personalized medicine. The company's focus on clinically actionable molecular tests and its strategic approach to gathering evidence for reimbursement suggest a clear path toward broader clinical adoption and commercial success. Future endeavors will likely involve scaling operations, expanding their test portfolio, and solidifying partnerships within the healthcare ecosystem to further their mission of improving patient outcomes through advanced diagnostics.
See full Interpace Biosciences company page
